Avanir Pharma soars on agitation drug study

September 15, 2014 6:53 PM

3 0

NEW YORK (AP) — Shares of Avanir Pharmaceuticals soared Monday after the company reported positive clinical trial results for a drug that is designed to treat agitation in Alzheimer's disease patients.

The company said patients who were treated with AVP-923 were less agitated than patients given a placebo. The mid-stage clinical study lasted 10 weeks and included 220 patients, and the patients were evaluated with a questionnaire used to measure disturbance in patients with dementia.

Also read: Celgene quarterly revenue rises 28 percent as Revlimid shines

Read more

To category page